Tapan Desai, MD
Pulmonary Disease · Crown Point, INNPI 1255579876
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Grifols USA, LLC at 49.2% of the total. Reporting peaked in 2019 at $6,260 and has fallen 65.9% since, to $2,135 in 2025.
Across 194 payments — averaging $70.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$7K
- Inspire Medical Systems, Inc.$3K
- Pfizer$1K
- GSK$420
- AstraZeneca$335
- Jazz Pharmaceuticals Inc.$223
- plus $2K from 29 others
What the payments were for
- Consulting fees$1,1108%
- Speaking & faculty fees$5,70542%
- Travel & lodging$1,60312%
- Food & beverage$5,24738%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 12 | $6,725 |
| Inspire Medical Systems, Inc. | 22 | $2,601 |
| Pfizer | 1 | $1,110 |
| GSK | 44 | $420 |
| AstraZeneca | 22 | $335 |
| Jazz Pharmaceuticals Inc. | 6 | $223 |
| Boehringer Ingelheim | 13 | $209 |
| Itamar Medical Inc | 2 | $170 |
| Grifols Shared Services North America, Inc. | 2 | $162 |
| Regeneron Healthcare Solutions, Inc. | 4 | $148 |
| Novartis | 7 | $146 |
| Pulmonx Corporation | 1 | $146 |
| Intuitive Surgical | 1 | $135 |
| Johnson & Johnson(2 entities) | 6 | $116 |
| Abbott | 1 | $112 |
| Teva Pharmaceuticals USA, Inc. | 6 | $107 |
| Sunovion Pharmaceuticals Inc. | 9 | $107 |
| Mylan Specialty L.p. | 7 | $100 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $94 |
| Mallinckrodt Enterprises LLC | 4 | $80 |
| Medtronic | 3 | $75 |
| Actelion Pharmaceuticals US, Inc. | 3 | $68 |
| Genentech USA, Inc. | 4 | $50 |
| Amgen | 2 | $45 |
| Philips North America LLC | 1 | $26 |
| Sanofi | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| 3b Medical, Inc. | 1 | $18 |
| Circassia Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Electromed, Inc. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolastin-C$4,366
- Prolastin-C Liquid$2,235
- Inspire$1,992
- CHARTIS CATHETER$146
- ZEPHYR DELIVERY CATHETER$146
- ZEPHYR ENDOBRONCHIAL VALVE$146
- PULMONX CHARTIS TABLET CONSOLE$146
- Da Vinci Surgical System$135
- WatchPATONE$124
- PROCLAIM$112
- SUNOSI$105
How this compares
$13,665 in reported general payments places this provider in the 80th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 399 | $313,772 |
| OfevNintedanib Esylate | 16 | $185,836 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $178,970 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 144 | $121,058 |
| Spiriva RespimatTiotropium Bromide | 96 | $69,332 |
| Breo ElliptaFluticasone/Vilanterol | 120 | $67,979 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 99 | $64,049 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 98 | $62,655 |
| Incruse ElliptaUmeclidinium Bromide | 85 | $39,783 |
| Spiriva HandihalerTiotropium Bromide | 21 | $27,884 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $18,625 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 26 | $18,504 |
| Tiotropium Bromide | 15 | $15,740 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 87 | $13,507 |
| Advair HfaFluticasone Propion/Salmeterol | 34 | $12,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $420 | $492,884719 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $209 | $336,327236 claims |
| Grifols USA, LLCProlastin C | $6,725 | $178,97012 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $335 | $145,457217 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $107 | $5,53516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Crown Point
- Giovanni InfusinoCrown Point$526K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
- Rajeev MehtaMuncie$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.